📰 Priority Review News
Page 74 - Priority Review News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Priority Review. Real-time updates on events, politics, business and more.
February 23, 2023
Investegate announcements from Sanofi - Aventis Groupe, Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection
February 23, 2023
Genmab Publishes 2022 Annual ReportCompany AnnouncementCOPENHAGEN, Denmark; February 22, 2023 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2022. Below is a summary of business progress in 2022, financial performance for the year and the financial outlook for 2023. The fu...
February 23, 2023
/PRNewswire/ -- "2022 was a fantastic year for Calliditas as we launched TARPEYO® in the US, the first approved drug for IgA nephropathy and a medication with...
February 23, 2023
FDA approves once-weekly ALTUVIIIO, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection Paris and Stockholm - February 23
February 22, 2023
The FDA has accepted for Priority Review the BLA for RSVpreF (PF-06928316), a bivalent RSV vaccine candidate for administration to pregnant individuals.
February 22, 2023
The global Hand Eczema (HE) Treatment Market is predicted to generate a market value of US$ 53 Million in 2023 and a market value of US$ 114.42 Million by 2033, with a CAGR of 8% from 2023 to 2033. In the historical period 2018 to 2022, the market for Hand Eczema (HE) Treatment grew at a CAGR of 4%.According to Stud...
February 22, 2023
22.02.2023 - Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the company’s Biologics License Application (BLA) for elranatamab, an investigational B-cell maturation antigen (BCMA) ... Seite 1
February 22, 2023
NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) announced the FDA has granted Priority Review for the company's Biologics License Application for elranatamab for the treatment of patients with relapsed
February 20, 2023
The global Encephalitis Treatment Market is now assessed at US$ 20.14 billion in 2023, with a CAGR of 5.4% expected by 2033. Because to technology advancements in healthcare, the industry is expected to reach US$ 34.08 billion by 2033.The major factor attributing to the growth of the market is the high mortality and...
February 18, 2023
The FDA has accepted for review two sNDAs for Prevymis (letermovir).